iBio (IBIO)
(Delayed Data from AMEX)
$2.03 USD
+0.18 (9.73%)
Updated May 2, 2024 04:00 PM ET
After-Market: $2.02 -0.01 (-0.49%) 6:36 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
iBio, Inc. [IBIO]
Reports for Purchase
Showing records 1 - 14 ( 14 total )
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage to focus our efforts elsewhere in the biotechnology sector.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage and Placing Under Review
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
Deal with Caliber is the First One in Therapeutic Biologics Development
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
Marque GE Healthcare Partnership Has Been Renewed
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
CHMP Opinion on Elelyso Does Not Impact IBIO Potential
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
No More Mystery Whether the FDA Will Approve Plant-Produced Biologics
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: iBio, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a 12-month price target of $3.00
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
|